| Literature DB >> 24289243 |
Stefan Kurtenbach1, Sarah Kurtenbach, Georg Zoidl.
Abstract
BACKGROUND: Large data sets from gene expression array studies are publicly available offering information highly valuable for research across many disciplines ranging from fundamental to clinical research. Highly advanced bioinformatics tools have been made available to researchers, but a demand for user-friendly software allowing researchers to quickly extract expression information for multiple genes from multiple studies persists.Entities:
Mesh:
Year: 2013 PMID: 24289243 PMCID: PMC4222097 DOI: 10.1186/1756-0500-6-496
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Figure 1File organization. Files have to be organized as depicted. Folder names can be chosen differently, as long as they are numbered and numbers are separated with a space from rest of the name. If data in a study is non-logarithmic, user can include “NOLOG” in the respective data folder name. The folder SubVIs contains LabVIEW VI files that are required for ADE function.
Figure 2Program interface. While running, the program will indicate which genes were found in the dataset, which ones were not present in the array annotation (Annotation.txt file), and which genes are present in the chip annotation but not in the dataset. Progress bars indicate progress for data extraction, refinement, merging, and statistics. Statistics will only be performed when button is activated. In the settings tab on the left, the user can choose between median and mean values to be used for spot selection and ratio calculations. Further, Stouffer’s Z-transform method or Fisher’s method can be chosen to combine p-values from the studies. The user can also chose between automatic Log2 detection, or manual definition. In the latter case “NOLOG” has to be assigned to the folder names of the studies not Log2 transformed.
Figure 3Overview over ADE workflow.
Class A GPCRs significantly regulated in human heart disease
| P2RY13 | 0.00E + 00 | + | NPBWR1 | 7.37E-08 | - | GPR78 | 3.46E-05 | - |
| P2RY14 | 0.00E + 00 | + | PTGER2 | 7.82E-08 | - | HCRTR2 | 5.29E-05 | + |
| S1PR3 | 9.04E-52 | - | P2RY12 | 7.98E-08 | + | S1PR2 | 6.57E-05 | - |
| GPR4 | 2.80E-31 | - | GPR3 | 9.09E-08 | - | OPN3 | 7.01E-05 | - |
| P2RY2 | 3.08E-30 | - | CMKLR1 | 1.07E-07 | + | F2RL1 | 1.07E-04 | - |
| ADRB1 | 7.41E-21 | - | LPAR3 | 1.50E-07 | - | HTR7 | 1.37E-04 | - |
| MRGPRF | 5.41E-19 | - | P2RY11 | 1.68E-07 | - | S1PR4 | 1.50E-04 | - |
| C5AR1 | 3.34E-14 | - | TAAR1 | 1.21E-06 | - | GPR171 | 1.93E-04 | + |
| PTGER3 | 3.91E-13 | - | GPR84 | 1.25E-06 | - | MRGPRX2 | 2.40E-04 | - |
| GPR34 | 1.94E-12 | + | GALR2 | 1.64E-06 | - | GPR37L1 | 4.36E-04 | - |
| CXCR4 | 1.77E-11 | + | GPR161 | 2.88E-06 | - | HRH2 | 4.47E-04 | - |
| DARC | 3.48E-10 | - | RXFP3 | 3.60E-06 | - | CCR2 | 7.51E-04 | - |
| LTB4R | 2.98E-09 | - | TSHR | 5.54E-06 | - | BDKRB1 | 7.96E-04 | - |
| FPR2 | 6.92E-09 | - | ADRA1B | 7.49E-06 | - | | | |
| HTR2B | 3.19E-08 | + | P2RY6 | 8.14E-06 | - |
47 of 288 class A GPCRs are differentially expressed in heart disease (p < 0.001). List of receptors was derived from the website of the International Union of Basic and Clinical Pharmacology (http://www.iuphar-db.org). Data was combined from 12 studies, containing 25 groups and 14 different cardiomyopathies: human arrhythmogenic right ventricular cardiomyopathy (ARVC, 1 group, 12 samples, 12 controls), dilated cardiomyopathy (DCM, 13 groups, 241 samples, 127 controls), doxorubicin induced cardiomyopathy (DOX, 1 group, 7 samples, 8 controls), fetal cardiomyopathy (FCM, 1 group, 5 samples, 5 controls), valvular cardiomyopathy (VCM, 1 group, 7 samples, 11 controls), hypertrophic cardiomyopathy (HCM, 3 groups, 119 samples, 55 controls), and ischemic cardiomyopathy (ICM, 5 groups, 166 samples, 52 controls). p-value represents combined p-values using Stouffer’s Z-transform method. +/- indicates up- or down-regulation reported by > 75% of the studies.